Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Pulse Biosciences, Inc.

NASDAQ: PLSE · Industrial Applications and Services · 7 alerts · CIK 1625101

Pulse Biosciences, Inc. stories on ALFA USA NewsRead the news →
Share price
$46.36Close, Nov 16
Market cap
$3.41B
Shares outstanding
73.55MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Pulse Biosciences, Inc. filings on SEC EDGAR ↗

8:41 AM ET 8-K
Clinical Trial Data

Pulse Biosciences Clinical Trial Data

Pulse Biosciences announced interim six-month results from its PRECISE-BTN multicenter U.S. study evaluating the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules. The data showed that 86% of patients achieved the primary endpoint of at least 50% nodule volume reduction, with a median reduction of 72% and no serious adverse events reported. These results demonstrate the safety and efficacy of the company's nonthermal Nanosecond Pulsed Field Ablation (nsPFA) technology in a clinical setting.

9:07 AM ET 8-K
Clinical Trial Data

Pulse Biosciences Clinical Trial Data

Pulse Biosciences reached its enrollment target of 164 evaluable patients in the NANOPULSE-AF IDE pivotal clinical study three months ahead of schedule. The study evaluates the safety and effectiveness of the nPulse Cardiac Catheter System for treating drug-resistant paroxysmal atrial fibrillation. Primary safety and effectiveness endpoints will be assessed at 6 and 12 months post-ablation to support future regulatory submissions.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.